Increased bone marrow microvessel density in newly diagnosed multiple myeloma carries a poor prognosis.

Abstract:

:Solid organ tumors associated with neoangiogenesis, as measured by increased microvessel density (MVD), have poorer prognoses. A similar observation of increased MVD has been made in hematologic malignancies; however, its prognostic significance remains unknown. We investigated changes in MVD in 122 newly diagnosed multiple myeloma patients uniformly treated according to the "Total Therapy" protocol (remission induction followed by tandem autotransplants and interferon maintenance) from a set of 231 patients. MVD was measured as mean of 10 fields (MVD) and the single highest field (SHF) on anti-CD34-stained Zenker-fixed paraffin-embedded bone marrow biopsy sections at 400x magnification. MVD was markedly elevated in this population, with a median of 4.4 vessels/field (range, 0.6 to 55.7), and SHF was 13 vessels/field (range, 2 to 80). When compared to 54 patients with less than 4 MVD, 67 patients with mean MVD of greater than 4 had a significantly inferior median duration of event-free survival (EFS) (2.7 v 4.3 years; P =.03), overall survival (OS) (4.3 v 7.9+ years, P =.006), and median complete response (CR) duration (2.2 v 6.8+ years, P=.003). A similarly significant unfavorable relationship to EFS and OS was present for SHF greater than 13. On multivariate analysis of other previously recognized prognostic factors (beta(2)-microglobulin [beta2M], C-reactive protein [CRP], and Bartl grade; and deletion 13), MVD < or = 4 emerged as a major favorable prognostic variable for OS followed by CRP < or = 4, P=.006. Thus, tumor-associated angiogenesis as reflected by MVD is a biologically relevant and important prognostic feature that can be targeted by antiangiogenesis therapy such as thalidomide, which has remarkable antitumor activity in advanced and refractory multiple myeloma.

journal_name

Semin Oncol

journal_title

Seminars in oncology

authors

Munshi NC,Wilson C

doi

10.1016/s0093-7754(01)90025-9

subject

Has Abstract

pub_date

2001-12-01 00:00:00

pages

565-9

issue

6

eissn

0093-7754

issn

1532-8708

pii

S0093775401002688

journal_volume

28

pub_type

杂志文章
  • Lymphoma: diagnosis, staging, natural history, and treatment strategies.

    abstract::Non-Hodgkin's lymphoma (NHL) is not a single disease, but a group of closely related B- and T-cell cancers of the lymphatic system. The incidence of NHL is rising, particularly in the countries of the industrialized world. The increased incidence is poorly understood, but several risk factors have been postulated to b...

    journal_title:Seminars in oncology

    pub_type: 杂志文章

    doi:10.1053/j.seminoncol.2005.01.008

    authors: Zinzani PL

    更新日期:2005-02-01 00:00:00

  • Immunotherapeutic strategies for high-risk bladder cancer.

    abstract::Transitional cell carcinoma (TCC), which is the pathological diagnosis for the majority of bladder cancers, is a solid tumor entity that is responsive to immunotherapy as evidenced by a substantial cure rate documented with the use of intravesical bacillus Calmette-Guérin (BCG) therapy in selected patients with high-g...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2006.12.004

    authors: Sharma P,Old LJ,Allison JP

    更新日期:2007-04-01 00:00:00

  • Preliminary experience with paclitaxel in advanced bladder cancer.

    abstract::In a phase II Eastern Cooperative Oncology Group trial, single-agent paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) was administered to 26 patients with advanced urothelial cancer who had not received prior systemic chemotherapy. Paclitaxel was given at a dose of 250 mg/m2 by 24-hour continuous infusi...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Roth BJ

    更新日期:1995-06-01 00:00:00

  • Current treatment of medulloblastoma: recent advances and future challenges.

    abstract::Medulloblastoma (MB) is the most common malignant brain tumor of childhood, yet it makes up only 1% of adult brain tumors. MB is uniquely sensitive to chemotherapy and radiation, but successful surgical resection continues to be an important component of therapeutic success. Progress in the treatment of MB has occurre...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2004.07.009

    authors: Rood BR,Macdonald TJ,Packer RJ

    更新日期:2004-10-01 00:00:00

  • African American men, prostate cancer early detection examination use, and informed decision-making.

    abstract::It is well known that African American men are more likely to be diagnosed with metastatic prostate cancer than White men. Racial variation in the use of prostate cancer early detection modalities (ie, digital rectal examination [DRE] and prostate-specific antigen [PSA] testing) has been suggested as a major reason fo...

    journal_title:Seminars in oncology

    pub_type: 杂志文章

    doi:

    authors: Myers RE

    更新日期:1999-08-01 00:00:00

  • Central nervous system disease in hematologic malignancies: historical perspective and practical applications.

    abstract::Acute lymphoblastic leukemia (ALL) 5-year survival rates are approaching 90% in children and 50% in adults who are receiving contemporary risk-directed treatment protocols. Current efforts focus not only on further improving cure rate but also on patient quality of life. Hence, all protocols decrease or limit the use ...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2009.05.002

    authors: Pui CH,Thiel E

    更新日期:2009-08-01 00:00:00

  • On the frontline of screening for breast cancer.

    abstract::The mainstay of screening for breast cancer is the mammogram. There are several randomized control trials that demonstrate a significant decrease in breast cancer mortality when compared to women without screening mammography included in their care. Digital mammography has improved detection in the dense breast. With ...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2010.11.004

    authors: D'Orsi CJ,Newell MS

    更新日期:2011-02-01 00:00:00

  • Characterization of outcomes in patients with metastatic non-small cell lung cancer treated with programmed cell death protein 1 inhibitors past RECIST version 1.1-defined disease progression in clinical trials.

    abstract::Based on anecdotal cases of clinically important decreases in tumor size following initial evidence of disease progression when treating patients with anti-PD-1 therapies, investigators have conducted clinical trials in patients with metastatic non-small lung cancer (mNSCLC) receiving anti-PD-1 therapy allowing for tr...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,多中心研究,评审

    doi:10.1053/j.seminoncol.2017.01.001

    authors: Kazandjian D,Keegan P,Suzman DL,Pazdur R,Blumenthal GM

    更新日期:2017-02-01 00:00:00

  • Small cell carcinoma of the head and neck: a review.

    abstract::Small cell carcinoma (SCC) has become recognized as a distinct, though relatively infrequent, clinical pathology that occurs in multiple sites throughout the head and neck. Excluding cases that are considered to arise from skin, SCC in the head and neck has been found to develop in nearly all structures associated wit...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2006.10.024

    authors: Renner G

    更新日期:2007-02-01 00:00:00

  • Liver transplantation in Langerhans' cell histiocytosis (histiocytosis X).

    abstract::Two children with biopsy-proven LCH underwent successful hepatic transplantation for end-stage liver disease. These patients were thought not to have active LCH disease at the time of transplantation, although one had developed a new osteolytic lesion a few months before the operation and the other had suspicious oste...

    journal_title:Seminars in oncology

    pub_type: 杂志文章

    doi:

    authors: Concepcion W,Esquivel CO,Terry A,Nakazato P,Garcia-Kennedy R,Houssin D,Cox KL

    更新日期:1991-02-01 00:00:00

  • The current status of toxicity protectants in cancer therapy.

    abstract::Current therapies for the treatment of malignancies are associated with significant toxicity, as chemotherapy and radiation therapy do not discriminate between normal and malignant cells. One approach to ameliorating the toxicity associated with therapy is through the use of chemoprotective agents. This article review...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Schuchter LM,Luginbuhl WE,Meropol NJ

    更新日期:1992-12-01 00:00:00

  • Review of regional therapy of liver metastases in colorectal cancer.

    abstract::Hepatic metastases are a major cause of mortality in patients with colorectal carcinoma. The rationale for regional therapy is presented. The randomized studies are reviewed and they demonstrated a significantly higher response rate with hepatic arterial therapy versus systemic therapy. Survival information is difficu...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Kemeny N

    更新日期:1992-04-01 00:00:00

  • Treatment of chronic myelogenous leukemia with different cytokines.

    abstract::In vitro data suggest a synergistic antiproliferative effect of different cytokines. In four clinical studies chronic myelogenous leukemia (CML) patients were treated with interferon (IFN)-alpha alone or IFN-alpha combined with either low-dose IFN-gamma or tumor necrosis factor (TNF)-alpha. The best response was achie...

    journal_title:Seminars in oncology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:

    authors: Wandl UB,Opalka B,Kloke O,Nagel-Hiemke M,Moritz T,Niederle N

    更新日期:1992-04-01 00:00:00

  • Implications of the new biology for therapy in breast cancer.

    abstract::It is a truism that a better understanding of the biology of breast cancer should lead to improvements in diagnosis and therapy. Despite this, our significantly improved grasp of breast cancer biology has had little direct therapeutic impact to date. The technologies used to treat breast cancer (surgery, radiation the...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Sledge GW Jr

    更新日期:1996-02-01 00:00:00

  • Rituximab in combination with CHOP or fludarabine in low-grade lymphoma.

    abstract::Non-Hodgkin's lymphoma (NHL) is composed of a group of lymphoid malignancies that has been increasing in incidence at an annual rate of 4% to 7% over the last 20 years in both the United States and Europe. The reasons for this rise in incidence in NHL are not yet defined but most likely involve environmental exposures...

    journal_title:Seminars in oncology

    pub_type: 杂志文章

    doi:10.1053/sonc.2002.30152

    authors: Czuczman MS,Fallon A,Mohr A,Stewart C,Bernstein ZP,McCarthy P,Skipper M,Brown K,Miller K,Wentling D,Klippenstein D,Loud P,Rock MK,Benyunes M,Grillo-López AJ,Bernstein SH

    更新日期:2002-02-01 00:00:00

  • Treatment of cancer-related hypercalcemia.

    abstract::Hypercalcemia, a complication that develops in 10% to 20% of patients with cancer, results from disruption of the normal physiologic mechanisms that closely regulate calcium homeostasis. Most patients with hypercalcemia are seriously dehydrated, and this volume depletion further compromises the kidney's ability to exc...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Ritch PS

    更新日期:1990-04-01 00:00:00

  • The new staging system for cutaneous melanoma in the era of lymphatic mapping.

    abstract::In 2002, the American Joint Committee on Cancer (AJCC) revised the staging system for cutaneous melanoma on the basis of a survival analysis of important melanoma prognostic factors. Features of the revised system include new strata for primary tumor thickness, incorporation of primary tumor ulceration as an important...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2004.03.018

    authors: Rousseau DL Jr,Gershenwald JE

    更新日期:2004-06-01 00:00:00

  • Megestrol acetate used as primary hormonal therapy in stage D prostatic cancer.

    abstract::The majority of patients with advanced prostatic cancer respond either to castration or estrogen therapy. In an attempt to identify an alternative hormonal therapy, 25 symptomatic stage D prostate cancer patients were treated with megestrol acetate as initial hormonal therapy. Thirty-three patients were evaluable for ...

    journal_title:Seminars in oncology

    pub_type: 杂志文章

    doi:

    authors: Bonomi P,Pessis D,Bunting N,Block M,Anderson K,Wolter J,Rossof A,Slayton R,Harris J

    更新日期:1985-03-01 00:00:00

  • Cisplatin and platinum analogues in breast cancer.

    abstract::Therapy for metastatic breast cancer can palliate disease and prolong life, but cannot cure. New drugs will be required if this is to change. Cisplatin and its analogue carboplatin offer new approaches to the treatment of metastatic breast cancer. Cisplatin has significant single-agent, front-line activity in metastat...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Sledge GW Jr

    更新日期:1992-02-01 00:00:00

  • Kinetic concepts in the systemic drug therapy of breast cancer.

    abstract::Optimal management of cancer today requires a thorough and up-to-date understanding of cancer cell kinetics and biochemistry. This report reviews the history and current standards in these fields and how they affect the contemporary approach to breast cancer management. Also outlined are recommended avenues for future...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Norton L

    更新日期:1999-02-01 00:00:00

  • Radiation therapy in pregnancy: risk calculation and risk minimization.

    abstract::The benefits of radiation therapy (RT) as part of a treatment regimen for cancer must be weighed against the potential risk of harm to the patient and in the pregnant patient, the risk to the developing fetus. Information necessary for determining the potential effects of RT on the developing fetus include the gestati...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Greskovich JF Jr,Macklis RM

    更新日期:2000-12-01 00:00:00

  • Pharmacokinetics of paclitaxel and carboplatin in combination.

    abstract::We studied the pharmacokinetics of paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) and carboplatin administered in combination to 21 patients with advanced non-small cell lung cancer. Paclitaxel was administered as a 24-hour intravenous infusion at doses of 135 to 200 mg/m2. Carboplatin, dosed to a tar...

    journal_title:Seminars in oncology

    pub_type: 临床试验,杂志文章

    doi:

    authors: Kearns CM,Belani CP,Erkmen K,Zuhowski M,Hiponia D,Zacharski D,Engstrom C,Ramanathan R,Trenn MR,Aisner J

    更新日期:1995-10-01 00:00:00

  • From monoclonal antibodies to chimeric antigen receptors for the treatment of human malignancies.

    abstract::Monoclonal antibodies (mAbs) and their directly derived cell-based application known as chimeric antigen receptors (CARs) ensue from the need to develop novel therapeutic strategies that retain high anti-tumor activity, but carry reduced toxicity compared to conventional chemo- and radiotherapies. In this concise revi...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2014.08.005

    authors: Caruana I,Diaconu I,Dotti G

    更新日期:2014-10-01 00:00:00

  • Single-agent gemcitabine in non-small cell lung cancer: the French experience.

    abstract::Gemcitabine is a novel nucleoside analogue that has demonstrated activity against several solid tumors. A large phase II study has been performed in Europe and Canada with a total enrollment of 161 non-small cell lung cancer patients, 26 of whom were from the Institut Gustave-Roussy. Patient characteristics were the s...

    journal_title:Seminars in oncology

    pub_type: 临床试验,杂志文章,多中心研究

    doi:

    authors: Le Chevalier T,Gottfried M

    更新日期:1997-04-01 00:00:00

  • Clinical pharmacokinetics of fluorouracil and folinic acid.

    abstract::This article deals with the pharmacokinetics of fluorouracil (5-FU) and folinic acid (CHO-THF). 5-FU kinetics are characterized by short serum half-life times of 4.5 to 13 minutes. The high body clearance is mainly caused by a rapid catabolism of 5-FU to dihydrofluorouracil (FUH2), alpha-fluoro-ureidopropionic acid (F...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Schalhorn A,Kühl M

    更新日期:1992-04-01 00:00:00

  • Docetaxel (Taxotere) and gemcitabine in the treatment of non-small cell lung cancer: preliminary results.

    abstract::A phase II study was performed to investigate the tolerance and efficacy of the combination of docetaxel (Taxotere; Rhône-Poulenc Rorer, Antony, France) and gemcitabine in chemotherapy-naive patients with advanced non-small cell lung cancer (NSCLC). To date, 24 patients (five with stage IIIB and 19 with stage IV NSCLC...

    journal_title:Seminars in oncology

    pub_type: 临床试验,杂志文章,多中心研究

    doi:

    authors: Georgoulias V,Kourousis C,Androulakis N,Kakolyris S,Dimopoulos MA,Bouros D,Papadimitriou C,Hatzakis K,Heras P,Kalbakis K,Kotsakis T,Vardakis N,Meramveliotakis N,Hatzidaki D

    更新日期:1997-08-01 00:00:00

  • Preclinical experience with docetaxel in gastrointestinal cancers.

    abstract::Docetaxel is a semisynthetic taxane that acts primarily by promoting microtubule assembly and preventing the depolymerization of assembled microtubules, thereby inducing mitotic block and inhibition of cell proliferation. This agent also induces apoptosis and appears to prevent angiogenesis. Although docetaxel has sho...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2005.04.002

    authors: Bekaii-Saab TS,Villalona-Calero MA

    更新日期:2005-04-01 00:00:00

  • Oxygen status of malignant tumors: pathogenesis of hypoxia and significance for tumor therapy.

    abstract::Hypoxic areas are a characteristic property of solid tumors. Hypoxia results from an imbalance between the supply and consumption of oxygen. Major pathogenetic mechanisms for the emergence of hypoxia are (1) structural and functional abnormalities in the tumor microvasculature; (2) an increase in diffusion distances; ...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1016/s0093-7754(01)90210-6

    authors: Vaupel P,Kelleher DK,Höckel M

    更新日期:2001-04-01 00:00:00

  • Array-based cytogenetic approaches in acute myeloid leukemia: clinical impact and biological insights.

    abstract::Conventional cytogenetic studies have shown that the clinical and biological diversity of acute myeloid leukemia (AML) can be attributed, in part, to distinct chromosome aberrations, several of which are now routinely used for diagnosis, risk stratification, and outcome prediction. Although chromosome banding analysis...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2011.11.005

    authors: Bullinger L,Fröhling S

    更新日期:2012-02-01 00:00:00

  • In situ use of suicide genes for cancer therapy.

    abstract::Gene therapy has now become a standard experimental approach for treating cancers that have failed conventional therapies. As the understanding of the molecular nature of carcinogenesis develops, new approaches are being taken to directly target tumor cells, thus bypassing the difficulties of killing cells that are re...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Freeman SM,Whartenby KA,Freeman JL,Abboud CN,Marrogi AJ

    更新日期:1996-02-01 00:00:00